MEFS Exchange course - ESHRE2019
Pre-treatment strategies in assisted reproductive technology: Does the management of pre-existing gynecologic and endocrine conditions improve the outcome of ART cycles?
Precongress Course 16
Sunday 23 June 2019
Course type
Advanced and Basic
Course co-ordinator(s) Johnny Awwad (Lebanon) and Mohammad Aboulghar (Egypt)
Course description Beyond technological advances, the success of Assisted Reproductive Technology also depends on the personal characteristics of the patient undergoing the procedure. Some of these characteristics may represent pre-existing benign gynecological conditions, e.g. endometriosis, fibroids, adenomyosis, hydrosalpinx, uterine adhesions; or endocrine disorders, e.g. hypothyroidism, hyperprolactinemia and PCOS. The decision to address these conditions prior to the IVF/ICSI treatment cycle may often lead to unnecessary and potentially harmful interventions, and should therefore be based on established scientific evidence. This Precongress Course discusses some of these gynecological/endocrine conditions, their impact on the success of IVF/ICSI and the efficacy of proposed pre-treament strategies in view of emerging scientific evidence.
Target audience
- Reproductive Endocrinologists and Fertility Specialists
- Biologists involved in Assisted Reproductive Technologies
- Policy Regulators and Representatives of Third Party Payers
Educational needs and expected outcomes
At the completion of this pre-congress course, participants should be able to:
- Describe the mechanisms by which specific gynecologic and endocrine conditions affect the outcome of IVF/ICSI cycles
- Appraise the literature regarding common practices resulting in potential harm and no proven benefit
- Understand the cost effectiveness of surgical and medical inerventions proposed as IVF/ICSI pre-treatments to improve outcome
- Develop an evidence-based decision tree on when and if these interventions are efficacious and medically indicated
Programme
Sunday 23 June 2019
Chair: Johnny Awwad, Lebanon 09:00 - 09:30 Pre-IVF treatment of endometriosis: What, when and for how long? Johnny Awwad, Lebanon 09:30 - 09:45 Discussion 09:45 - 10:15 Pre-IVF treatment of uterine fibroids: When does intervention become beneficial? Mohamed Aboulghar, Egypt 10:15 - 10:30 Discussion 10:30 - 11:00 Coffee break Chair: Michel Abou Abdallah, Lebanon 11:00 - 11:30 Pre-IVF treatment of uterine adenomyosis: Is intervention useful at all? Togas Tulandi, Canada 11:30 - 11:45 Discussion 11:45 - 12:15 Pre-IVF treatment of severe tubal disease: To treat or not to treat? John Petrozza, U.S.A. 12:15 - 12:30 Discussion 12:30 - 13:30 Lunch break Chair: Michel Abou Abdallah, Lebanon 13:30 - 14:00 Pre-IVF treatment of uterine cavity defects: The do’s and the don’ts Togas Tulandi, Canada 14:00 - 14:15 Discussion 14:15 - 14:45 Pre-IVF thyroid function screening –why test, what to test and how to interpret Lubna Pal, U.S.A. 14:45 - 15:00 Discussion 15:00 - 15:30 Coffee break Chair: Mohamed Aboulghar, Egypt 15:30 - 16:00 Pre-IVF management of PCOS: How significant is the role of insulin sensitizers? Lubna Pal, U.S.A. 16:00 - 16:15 Discussion 16:15 - 16:45 Pre-IVF management of poor response: Much ado about nothing? John Petrozza, U.S.A. 16:45 - 17:00 Discussion
https://www.eshre.eu/ESHRE2019/Programme/Precongress-Courses/Course-16-MEFS
|